Drug intelligence / Profile preview

bevacizumab + cyclophosphamide + docetaxel + doxorubicin

Development stage: Unknown
Lead developer: Genentech
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination therapy consisting of four distinct drugs: Bevacizumab (Avastin) - a monoclonal antibody that targets vascular endothelial growth factor (VEGF); Cyclophosphamide - a chemotherapy agent; Docetaxel - a chemotherapy agent; Doxorubicin - a chemotherapy agent. Bevacizumab is an angiogenesis inhibitor that works by preventing the formation of new blood vessels in tumors. The combination likely represents an intensive chemotherapy regimen with the addition of targeted anti-angiogenic therapy for treating certain types of cancer.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + cyclophosphamide + docetaxel + doxorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + cyclophosphamide + docetaxel + doxorubicin.

Explore the full profile